Wednesday, August 10, 2022 7:36:33 AM
Literature Database
Hemoadsorption for severe MIS-C in critically ill children, should we consider it as a therapeutic opportunity?
Gabriella Bottari1, Flavia Severini2, Anna Hermine Markowich2, Giulia Lorenzetti2, Juan Carlos Ruiz Rodriguez3,4, Ricard Ferrer3,4, Paola Francalanci5, Antonio Ammirati6, Paolo Palma7 and Corrado Cecchetti1 |1 Pediatric Intensive Care Unit, Pediatric Emergency Department, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy | 2 Department of Pediatrics, University of Rome Tor Vergata, Residency School of Pediatrics, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy | 3 Intensive Care Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain | 4 Shock, Organ Dysfunction and Resuscitation Research Group, Vall d’Hebron Research, Institute (VHIR), Barcelona, Spain | 5 Unit of Pathology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy | 6 Pediatric Emergency Unit, Pediatric Emergency Department, Bambino Gesù Children’s Hospital, IRCSS, Rome, Italy Int J Artif Organs 2022; epub
08/10/2022
New!PediatricsPeer Reviewed Published DataReduction in catecholaminesReviewSafetyViral infectionCase of the weekCase reportCOVID-19Critical CareCRRT (pre or post filter)Inflammatory parameters
Download documentDownload documentLink to source
Summary
CoW 32/2022 – This case reports on a 13 year old boy (weight 60 kg, height 160 cm) who presented with fever, rash, abdominal pain, and vomiting.
Summary
Multisystem inflammatory syndrome (MIS-C) is a new severe clinical condition that has emerged during the COVID-19 pandemic and affects children and the young usually after a mild or asymptomatic COVID-19 infection. Symptoms commonly include cardiovascular dysfunction for which support is required in the majority of cases. In the case report a 13 yr old boy with refractory shock secondary to left ventricular dysfunction (LVD) in the context of MIS-C, the use of hemoadsorption with CytoSorb is described. The therapeutic strategy resulted in hemodynamic and clinical stabilization (reduction then cessation of vasopressors) as well as control of the hyperinflammatory response (including C-Reactive Protein, interleukin – IL-6 and IL-10). The patient received in total 5 adsorbers over 72 hrs. with the first 2 adsorbers for 12 hours each, and a further 3 adsorbers for 24 hours each inserted into the continuous renal replacement circuit. Treatment appeared to be safe and feasible. The authors then compare this case with two more published cases where CytoSorb has been used as an adjuvant therapy in similarly critically ill children with severe forms of MIS-C. All three patients responded with a prompt improvement in their myocardial function (within the first 24 h) following the start of hemadsorption. The authors state that using this blood purification strategy could be a therapeutic opportunity in severe LVD due to MIS-C, sparing the need for extracorporeal membrane oxygenation (ECMO) and other mechanical cardiocirculatory supports, with the advantage of it being less invasive. They also state that CytoSorb does not appear to interfere with most common immunomodulatory therapies although further evidence is required.
Case presentation
Blood tests revealed elevated leukocytes with neutrophilia, high C-reactive protein (CRP) (29.31 mg/gL), procalcitonin (3.32 ng/mL), and hyperferritinemia (1529 ng/mL)
He had a positive history for SARS-CoV-2 infection 6 weeks previously with positive serology
Within 24 h he developed diarrhea, poor pallor, and hypotension
Cardiac markers were elevated, and 2D-echocardiogram showed left ventricular (LV) dysfunction (Ejection Fraction EF 35%)
Supportive care with milrinone and dopamine was started and, as multisystem inflammatory syndrome in children (MIS-C) was suspected, he received immunoglobulins and corticosteroids
The following day he deteriorated, with an 2D-echocardiogram showing a LVEF of 25%, therefore he was referred to the pediatric intensive care unit (PICU) requiring endotracheal intubation and invasive mechanical ventilation (IMV) due to cardiogenic shock
Given the increase in troponin I (high sensitivity troponin, hs-TnI) levels from 75 to 1200 pg/ml in 12 h, infectious myocarditis was suspected and an endomyocardial biopsy (EMB) was taken
Considering the clinical picture of hyperinflammation associated severe shock due to left ventricular dysfunction (LVD) and high lactate (7.9 mmol/l) with the need for high inotropic and vasopressor support (epinephrine 0.35 µ/kg/min, norepinephrine 0.06 µ/kg/min, and milrinone 0.5 µ/kg/min), hemoadsorption with CytoSorb was started in combination with continuous kidney replacement therapy (CKRT)
Of note, even though the patient fulfilled the diagnostic criteria of MIS-C, the authors could not completely rule out the development of fulminant myocarditis due to Parvovirus B19 (PVB19) positivity after suffering from COVID-19, which is why corticosteroids were withheld and immunoglobulins and anakinra were maintained
Treatment
The patient received in total 5 adsorbers over 72 hrs with the first 2 adsorbers for 12 hours each, and a further 3 adsorbers for 24 hours each inserted into the continuous renal replacement circuit
Anticoagulation protocol: citrate-calcium
Measurements
Hemodynamics and requirements for vasoactive substances
Inflammatory parameters
Left ventricular ejection fraction
Cardiac enzymes
Safety
Results
The therapeutic strategy resulted in hemodynamic stabilization with a rapid reduction followed by the cessation of vasopressors at the time of discontinuation of CytoSorb therapy
Treatment was also associated with control of the hyperinflammatory response as evidenced by a reduction in inflammatory parameters including CRP, interleukin – IL-6 and IL-10
After the first 24 h of combined hemoadsorption and CKRT therapy, an improvement in the LVEF to 50% was observed
Troponin I levels decreased from 1200 pg/ml to around 375 pg/ml within 12 hours of treatment with decreasing levels thereafter, reaching ~100 pg/ml by the end of blood purification therapy
No adverse events were noted
Patient Follow-up
CKRT was discontinued at the same time of hemoperfusion after 72 h (day 3)
He was weaned off invasive mechanical ventilation on day 6 and discharged from the PICU on day 8
After 2 weeks his cardiac function had completely restored and the patient was discharged from the hospital on day 20 requiring only the diuretic, spironolactone
Conclusion
In this adolescent with refractory shock secondary to LV dysfunction in the context of MIS-C, treatment with hemoadsorption in combination with immunomodulatory therapies resulted in hemodynamic and clinical stabilization as well as control of the hyperinflammatory response with the treatment appearing safe and feasible
The authors compare this case with two more published cases where CytoSorb has been used as an adjuvant therapy in similarly critically ill children with severe forms of MIS-C. All three patients responded with prompt improvements in their myocardial function (within the first 24 h) following the start of hemoadsorption
The authors state that using this blood purification strategy could be a therapeutic opportunity in severe LVD due to MIS-C, sparing the need for extracorporeal membrane oxygenation (ECMO) and other mechanical cardiocirculatory supports, with the advantage of it being less invasive. They also state that CytoSorb does not appear to interfere with most common immunomodulatory therapies although further evidence is required.
Recent CTSO News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 09:14:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 09:11:21 PM
- CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress • GlobeNewswire Inc. • 07/17/2024 11:00:00 AM
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
FEATURED North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • Aug 5, 2024 9:00 AM
Fifty 1 Labs, Inc. and All-In-Extracts Announce Joint Venture to Develop and Release New Testosterone Boosting Supplement • BLEG • Aug 5, 2024 8:30 AM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM